LAWRENCE, Mass., Nov. 11, 2015 /PRNewswire/ -- In honor of Veteran's Day, NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of dialysis products, is highlighting its commitment to enabling the delivery of renal replacement therapy (RRT) for the U.S. military. Given its unique design and features, which include menu-driven graphical user interface controls, volumetric balancing, simple button options, integrated cartridges, pre-mixed dialysate solutions, and simple effluent drainage capability, the portable NxStage® System One™ is capable of providing access to renal replacement therapy (RRT) at combat support hospitals to help severely wounded soldiers with acute kidney injury (AKI).
Improvements in early combat casualty care management are potentially lifesaving. Recent research1 shows that early RRT can help patients survive casualties and reduce risks of early complications of AKI, typically caused by large soft tissue damage resulting from explosive devices. The results demonstrate that RRT can be safely applied in a combat hospital environment and is likely to allow for safe long-range transport to care facilities in safe havens for even the most critically injured service members.
"At NxStage, we remain committed to further developing flexible technologies to give patients access to renal care, wherever they are," said Jeff Burbank, CEO of NxStage Medical. "We believe the System One's unique design enables it to meet the demands and challenges of our military and provide care to severely wounded soldiers around the world."
For more information about the System One, please visit www.nxstage.com.
About The NxStage System One
The System One is used to provide a range of flexible therapy options in hospitals and dialysis centers. The NxStage System One is also the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis and home nocturnal hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. In addition, NxStage's Nx2Me Connected Health platform collects important NxStage System One and patient information for flexible viewing, monitoring and reporting that may improve patient management and simplify alternative site care. http://www.nxstage.com/.
About NxStage Medical
NxStage Medical Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter September 30, 2015. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen K. Sheppard, Esq.
Tel: (978) 332-5923
1David Zonies, MD, MPH, Joseph DuBose, MD, Joel Elterman, MD, Todd Bruno, MD, Christian Benjamin, MD, Jeremy Cannon, MD, and Kevin K. Chung, MD. Early implementation of continuous renal replacement therapy optimizes casualty evacuation for combat-related acute kidney injury. J Trauma Acute Care Surg. 2013; Volume 75, Number 2, Supplement 2.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nxstage-affirms-commitment-to-provide-access-to-renal-replacement-therapy-to-us-military-with-system-one-300176763.html
SOURCE NxStage Medical, Inc.